WuXi Biologics CEO reports 945 integrated projects by 2025, including 74 Phase III and 25 commercial manufacturing.209 new projects in 2025, with 50% from U.S. clients.
In 2025, there were a total of 945 integrated projects, with 74 being in Phase III clinical development and 25 focused on commercial manufacturing. A record-breaking 209 new integrated projects were initiated in the same year, with around half of them stemming from clients based in the United States. Complex modalities form the primary growth driver for WuXi Biologics.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments